Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Bruce D. Steel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Beta
- 1.80
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 24.69
Financials
Revenue
$0.00-100.0%Net Income
$-4.69MEBITDA
$-5.11MFree Cash Flow
$-4.18MEPS (diluted)
$-0.04Shares Outstanding (diluted)
111.81M+857.3%Operating Expenses
$5.16MCash & Debt
$57.16MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-22.40M | $-0.39 |
| 2024 | $41.09M | $-8.07M | $-0.23 |
| 2023 | $36.08M | $-13.34M | $-0.38 |
| 2022 | $15.76M | $-62.43M | $-3.19 |
| 2021 | $0.00 | $-38.98M | $-1.35 |
| 2020 | $0.00 | $-29.81M | $-1.46 |
| 2019 | $0.00 | $-25.58M | $-1.47 |
| 2018 | $0.00 | $-13.25M | $-1.09 |
| 2017 | $0.00 | $-2.26M | $-0.13 |
Valuation
EQhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-28.57%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·5h ago·Neutral
Equillium to Participate in Stifel's 2026 Virtual Immunology and Inflammation Forum LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be participating in a fireside chat at Stifel's 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026 at 12:00pm EDT.
View source ↗ - Newsreuters.com·1d ago·Positive
EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon Australian miner EQ Resources said on Tuesday it would take a 10% stake in a joint venture with Nasdaq-listed Elmet Group and Blue Moon Metals to restart the Springer tungsten project in Nevada.
View source ↗
Earnings
Thu, Nov 12(in 8 weeks)
Consensus estimate $-0.05 per share
Typical surprise +25.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.04 vs $-0.05beat
- Wed, May 13$-0.06 vs $-0.04miss
- Wed, Mar 25$-0.04 vs $-0.07beat
- Thu, Nov 13$-0.06 vs $-0.14beat
- Thu, Aug 14$-0.16 vs $-0.14miss
- Wed, May 14$-0.24 vs $-0.23miss
Estimates and results for EQ via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EQ officers and directors.
- Bought
- —
- Sold
- $2.8m
0 trades
20 trades
- Zedelmayer Christinesold
- Connelly Stephensold
- Connelly Stephensold
- Tom Pennysold
- Zedelmayer Christinesold
- Zedelmayer Christinesold
- Zedelmayer Christinesold
- Zedelmayer Christinesold
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in EQ.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.